Loading clinical trials...
Loading clinical trials...
Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 18-40 Years
Conditions
Interventions
HBV-MPL vaccine
Engerix™-B
Locations
1
Belgium
GSK Clinical Trials Call Center
Ghent, Belgium
Start Date
March 1, 1997
Primary Completion Date
May 1, 1998
Last Updated
June 17, 2008
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions